Base to Base biotech podcast 77: ...
Base to Base biotech podcast 77: Transferring mammal traits to humans, and is injecting tumours a new way to kill cancer?
Base to Base Biotech di Jim Cornall
E77
25 set 2026
53:56
Note sull'episodio

This week, we chat with Evan Appleton, chief scientific officer and co-founder of Intertwined, a company focused on understanding mammalian evolved protective traits, and how they can be transferred to humans. And we chat with Lew Bender, CEO of Intensity Therapeutics, which is pioneering an intratumoral injection therapy primarily for breast cancer that not only kills the cancer cells in the tumour but throughout the body as well, acting as almost a cancer-killing vaccine.

Times:

04:22 Intertwined

29:06 Intensity Therapeutics

Intensity Therapeutics

Intensity is a late-stage clinical biotech company whose novel engineered chemistry enables aqueous cytotoxic-containing drug formulations to mix and saturate a tumou ... 

Parole chiave
biotech
biotechnology
cancer
Intertwined
Intensity Therapeutics